Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for ...
Nektar Therapeutics (NKTR) shares have been on investors’ radar with a strong rally over the past three months and a dramatic rebound year to date. While the company’s financial trajectory remains a ...
It has been about a month since the last earnings report for Nektar Therapeutics (NKTR). Shares have lost about 19.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Shares of Nektar Therapeutics (NASDAQ:NKTR) gained on Friday after Jefferies upgraded the stock, noting an attractive risk-reward setup ahead of a mid-stage trial readout for the company’s lead asset, ...
Nektar Therapeutics' REZPEG has emerged as a best-in-class, second-line therapy for moderate-severe atopic dermatitis, targeting IL4/13 non-responders without JAK-inhibitor side effects. REZPEG's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback